# US 8,784,807 B2 · Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,807 B2
- Document ID: US8784807B2
- Status: Granted
- Kind: B2
- Application number: 12/441,166
- Filed: 2007-09-24
- Published: 2010-06-03
- Granted: 2014-07-22
- Earliest claimed: 2006-09-22
- Assignees: St. Jude Children's Research Hospital
- Applicants: Dario Vignali; Creg Workman; Lauren Collison; Kate Vignali
- Inventors: Dario Vignali; Creg Workman; Lauren Collison; Kate Vignali
- Web page: https://patentgrep.com/patent/US8784807B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/39533: {against materials from animals}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 35/00: Antineoplastic agents
- C12N 5/0636: {T lymphocytes}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/35: Valency
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods for regulating T cell function in a subject, particularly regulatory T cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an Interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor. The invention further provides methods for enhancing the immunogenicity of a vaccine or overcoming a suppressed immune response to a vaccine in a subject, including administering to the subject a therapeutically effective amount of an IL35-specific binding agent and administering to the subject a vaccine. In one embodiment the vaccine is a cancer vaccine.

## Claims

### Claim 1

A method of inhibiting a regulatory T-cell function in a subject, comprising administering to a subject in need of inhibiting a regulatory T-cell function a therapeutically effective amount of a specific binding agent, wherein said specific binding agent comprises an antibody that inhibits Interleukin 35 (IL35) activity, wherein the therapeutically effective amount of said antibody inhibits a regulatory T-cell function in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said specific binding agent comprises an anti-IL35 antibody that specifically binds to the IL35 heterodimer.

### Claim 3 (depends on 1)

The method of claim 1, wherein said specific binding agent comprises an antibody that binds to the EBI3 subunit of IL35.

### Claim 4 (depends on 1)

The method of claim 1, wherein said specific binding agent comprises an antibody that binds to the p35 subunit of IL35.